GPW
Every company in the roster listed on GPW.
Every company in the roster listed on GPW.
2 of 2 companies
| Company | Pipeline | Most advanced | Next readout | Market cap | Cash & inv. | Runway | R&D / yr |
|---|---|---|---|---|---|---|---|
Celon PharmaCLN · GPW | 2 assets: 2 Ph 2 | CPL500036Phase 2 · Parkinson's DiseaseReliable signal | None on record | — | — | — | — |
Ryvu Therapeutics SARVU · GPW | 1 asset: 1 Ph 2 | RomaciclibPhase 2 · Acute Myeloid LeukemiaWeak signal | Dec 2026Romaciclib · Phase 2 | — | $17MDec 2025 | Ended Mar 2026 | $48M |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov). Cash shows its balance-sheet month; runway shows a month only when it comes from an earlier report.